Paediatric methylphenidate (Ritalin®) restrictive conditions of prescription in France

British Journal of Clinical Pharmacology

Volumn 57, Issue 1, 2004, Pages 115-116

  Frances, C ^a   Hoizey, G ^a   Millart, H ^a   Trenque, T ^a,b  

^a Centre Regional de Pharmacovigilance   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PSYCHOSTIMULANT AGENT;

AGITATION; ALOPECIA; ATTENTION DEFICIT DISORDER; CHILD CARE; CONVULSION; DRUG ABUSE PATTERN; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG LEGISLATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATIGUE; GENERAL PRACTICE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LETTER; MENTAL DISEASE; NEUROLOGIC DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DRUG AND NARCOTIC CONTROL; FRANCE; HUMANS; METHYLPHENIDATE; PRESCRIPTIONS, DRUG;

EID: 0346688576     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01943.x     Document Type: Letter

References (13)

1. Frances C, Germain ML, Millart H, Trenque T. Survey of methylphenidate use in France. European Pharmacological Societies (EPHAR) - Lyon, July 6th 2001 - Abstract.
2. French educational system on line. Available at http://www.education. gouv.fr Accessed 12 December 2001 and 2 July 2003.
3. Kewley GD. Attention deficit hyperactivity disorder is underdiagnosed and untreated in Britain. Br Med J 1998; 316: 1594-6.
4. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98: 1084-8.
5. Safer DJ, Malever M. Stimulant treatment in Maryland Public Schools. Pediatrics 2000; 106: 533-9.
6. Zito JM, Safer DJ, DosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283: 1025-30.
7. Brown RT, Freeman WS, Perrin JM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001, 107: URL. http://www.pediatrics.Org/cgi/content/full/107/3/E43.
8. World Health Organization. The International Classification Disease, 10th revision. Geneva: World Health Organization 1992.
9. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM IV). Washington, DC American Psychiatric Association 1994.
10. National Institute for Clinical Excellence. October 2000. Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit/ Hyperactivity Disorder (ADHD) in Childhood: Available at: http://www.nice.org. uk/pdf/Methylph-guidance13.pdfAccessedJune30th2003.
11. Ball C. Attention-deficit hyperactivity disorder and the use of methylphenidate - A survey of the views of general practitioners. Psychiatr Bull 2001; 25: 301-4.
12. Poulin C. Medical and non medical stimulant use among adolescents: from sanctioned to unsantioned use. CMAJ 2001; 165: 1039-44.
13. Garland EJ. Intranasal abuse of prescribed methylphenidate. J Am Acad Child Adolesc Psychiatry 1998; 37: 573-4.